Kidney Cancer News & Features
A new drug is proven more effective than standard therapies for advanced kidney cancer in patients with demonstrated drug resistance.
Four drugs that were recently approved by the FDA for the treatment of kidney cancer are being doubted for their clinical application.
Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for aggressive renal cell carcinoma (RCC).
Robotic inferior vena cava (IVC) thrombectomy successfully removes thrombus associated with kidney cancer
Inferior vena cava (IVC) thrombectomy is typically is performed via a large open incision, but recently the procedure was successfully performed robotically, using only seven small incisions.
The FDA has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma (RCC).
Kidney Cancer Videos
Kidney Cancer Clinical Trials
- Harms of Cigarette Smoking and Health Benefits of Quitting (Fact Sheet)
- Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions
- Late-Stage Lung Cancer Often Overtreated
- Biomarker May Predict Prognosis for Targeted Therapy in Patients With HER2-Negative Breast Cancer
- "Supportive care" may hold less stigma than "palliative care"
- Engineered Switch in Immune Cell Technology Makes Therapy More Precise, and Safer
- Testosterone Therapy Does Not Increase Aggressive Prostate Cancer Risk
- Laparascopic Surgery Does Not Improve Outcomes Over Open Resection for Rectal Cancer
- Bisphosphonates May Be Useful as Palliative Measure in Selected Patients
- Smokers and Nonsmokers Who Develop NSCLC Display Differences
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|